acetylglucosamine has been researched along with Barrett Esophagus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakayama, J; Yamanoi, K | 1 |
| Arakura, N; Hasebe, O; Iwaya, Y; Kitahara, K; Koide, N; Muraki, T; Nakayama, J; Shinji, A; Suga, T; Tanaka, E; Yamada, S; Yokosawa, S | 1 |
1 review(s) available for acetylglucosamine and Barrett Esophagus
| Article | Year |
|---|---|
Reduced αGlcNAc glycosylation on gastric gland mucin is a biomarker of malignant potential for gastric cancer, Barrett's adenocarcinoma, and pancreatic cancer.
Topics: Acetylglucosamine; Adenocarcinoma; Animals; Barrett Esophagus; Biomarkers, Tumor; Gastric Mucins; Glycosylation; Humans; Pancreatic Neoplasms; Stomach Neoplasms | 2018 |
1 other study(ies) available for acetylglucosamine and Barrett Esophagus
| Article | Year |
|---|---|
Reduced expression of αGlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma--a possible biomarker to predict the malignant potential of Barrett's oesophagus.
Topics: Acetylglucosamine; Adenocarcinoma; Aged; Aged, 80 and over; Animals; Barrett Esophagus; Biomarkers, Tumor; Case-Control Studies; CDX2 Transcription Factor; Disease Progression; Esophageal Neoplasms; Female; Homeodomain Proteins; Humans; Immunohistochemistry; Male; Mice; Middle Aged; Mucin-6; Polysaccharides | 2014 |